Latest Funding News

AuKing Mining Ltd has kicked off a $2 million share placement with a first tranche completed and seeks shareholder approval for the second. The company also plans a fresh marketing partnership with Singapore’s Bullseye Analytics, issuing options as part of the deal.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for four Australian iShares ETFs, outlining key dates and options for investors to reinvest dividends.

Strickland Metals has announced a $55 million institutional placement to fund an expanded drilling program and advance a Pre-Feasibility Study for its Rogozna gold project in Serbia, with major shareholders reaffirming their support.

Income Asset Management has resolved a protracted legal dispute with BGC involving former employees, agreeing to a $1.9 million settlement. A key shareholder has stepped in with a liquidity facility to support the company’s payment obligations.

Pinnacle Investment Management reported an 11% drop in net profit after tax for the first half of FY26, despite record net inflows and a strategic move to fully acquire Pacific Asset Management.

Pinnacle Investment Management reported a solid 13% increase in funds under management to $202.5 billion despite an 11% drop in half-year profit. The company declared a 29 cent interim dividend and advanced its international expansion with key acquisitions.

CVC Limited forecasts a substantial increase in its half-year net loss, prompting the board to suspend the interim dividend amid cashflow concerns.

Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.